Table 1. Patient and tumor characteristics in relation to HIF and EGFR-status of both tumors.
| N = 688 | First breast cancer, N (%) | Second breast cancer, N (%) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HIF1/EGFR missing for 97/88 BC1, 54/52 BC2 | HIF1-negative | HIF1-positive | P-valuea | EGFR-negative | EGFR-positive | P-valuea | HIF1-negative | HIF1-positive | P-valuea | EGFR-negative | EGFR-positive | P-valuea |
| N = 522 (88%) | N = 69 (12%) | N = 520 (87%) | N = 80 (13%) | N = 523 (82%) | N = 111 (18%) | N = 570 (90%) |
N = 66 (10%) |
|||||
| Date of diagnosis | 0.6 | 0.001 | 0.2 | 0.9 | ||||||||
| <1977 | 82 (92%) | 7 (8%) | 68 (75%) | 23 (25%) | 0 | 0 | 0 | 0 | ||||
| 1977–1986 | 158 (87%) | 23 (13%) | 159 (87%) | 24 (13%) | 102 (86%) | 16 (14%) | 107 (90%) | 12 (10%) | ||||
| 1987–1996 | 204 (87%) | 30 (13%) | 214 (90%) | 25 (10%) | 181 (82%) | 39 (18%) | 199 (90%) | 23 (10%) | ||||
| 1997–2007 | 78 (90%) | 9 (10%) | 79 (91%) | 8 (9%) | 240 (81%) | 56 (19%) | 264 (89%) | 31 (11%) | ||||
| Age at diagnosis | 0.009 | <0.001 | 0.03 | <0.001 | ||||||||
| <50 years | 140 (83%) | 29 (17%) | 139 (79%) | 37 (21%) | 52 (73%) | 19 (27%) | 54 (76%) | 17 (24%) | ||||
| ≥50 years | 382 (91%) | 40 (9%) | 381 (90%) | 43 (10%) | 471 (84%) | 92 (16%) | 516 (91%) | 49 (9%) | ||||
| Node status | 0.9 | 0.04 | 0.002 | 0.5 | ||||||||
| N0 | 323 (88%) | 43 (12%) | 317 (85%) | 57 (15%) | 289 (85) | 51 (15%) | 304 (90%) | 35 (10%) | ||||
| N+ | 165 (88%) | 23 (12%) | 172 (91%) | 17 (9%) | 141 (74) | 49 (26%) | 167 (88%) | 23 (12%) | ||||
| If N+ Median (range) | 3 (1–33) | 2 (1–12) | 2.5 (1–33) | 2.5 (1–10) |
2 (1–23) | 2 (1–21) | 2 (1–23) | 4 (1–11) | ||||
| Missing | 34 | 3 | 31 | 6 | 93 | 11 | 99 | 8 | ||||
| Size | 0.4 | 0.6 | 0.7 | 0.01 | ||||||||
| ≤20 mm | 312 (89%) | 38 (11%) | 314 (88%) | 43 (12%) | 366 (83%) | 75 (17%) | 406 (91%) | 38 (9%) | ||||
| >20 mm | 177 (87%) | 27 (13%) | 176 (86%) | 28 (14%) | 143 (82%) | 32 (18%) | 147 (84%) | 27 (16%) | ||||
| Median (range) | 18 (1–100) | 20 (1–70) | 17 (1–100) | 20 (1–70) | 15 (1–110) | 17 (1–80) | 15 (1–110) | 20 (1–80) | ||||
| Missing | 33 | 4 | 30 | 9 | 14 | 4 | 17 | 1 | ||||
| Stage | 0.4 | 0.3 | 0.008 | 0.1 | ||||||||
| I | 233 (89%) | 29 (11%) | 232 (87%) | 36 (13%) | 234 (86%) | 39 (14%) | 247 (90%) | 26 (10%) | ||||
| II | 163 (88%) | 22 (12%) | 162 (87%) | 24 (13%) | 123 (77%) | 36 (23%) | 142 (90%) | 16 (10%) | ||||
| III | 55 (85%) | 10 (15%) | 60 (92%) | 5 (8%) | 62 (75%) | 21 (25%) | 69 (83%) | 14 (17%) | ||||
| Missing | 71 | 8 | 66 | 15 | 104 | 15 | 112 | 10 | ||||
| ER-status | <0.001 | <0.001 | <0.001 | <0.001 | ||||||||
| <10% | 75 (76%) | 24 (24%) | 49 (51%) | 48 (49%) | 54 (52%) | 50 (48%) | 54 (52%) | 50 (48%) | ||||
| ≥10% | 442 (91%) | 44 (9%) | 464 (94%) | 29 (6%) | 463 (89%) | 57 (11%) | 507 (97%) | 14 (3%) | ||||
| Missing | 5 | 1 | 7 | 3 | 6 | 4 | 9 | 2 | ||||
| PR-status | <0.001 | <0.001 | <0.001 | <0.001 | ||||||||
| <10% | 132 (80%) | 33 (20%) | 110 (67%) | 53 (43%) | 145 (69%) | 65 (31%) | 158 (75%) | 52 (25%) | ||||
| ≥10% | 385 (92%) | 35 (8%) | 403 (94%) | 24 (6%) | 367 (90%) | 42 (10%) | 399 (97%) | 11 (3%) | ||||
| Missing | 5 | 1 | 7 | 3 | 11 | 4 | 13 | 3 | ||||
| HER2-status | 0.005 | 0.07 | <0.001 | 0.07 | ||||||||
| Negative (0 to 2+) | 482 (90%) | 56 (10%) | 476 (88%) | 68 (13%) | 495 (85%) | 85 (15%) | 526 (90%) | 56 (10%) | ||||
| Positive (3+) | 30 (75%) | 10 (25%) | 31 (78%) | 9 (23%) | 18 (49%) | 19 (51%) | 30 (81%) | 7 (19%) | ||||
| Missing | 10 | 3 | 13 | 3 | 10 | 7 | 14 | 3 | ||||
| Ki67 | <0.001 | <0.001 | <0.001 | <0.001 | ||||||||
| ≤20 | 440 (93%) | 34 (7%) | 440 (92%) | 39 (8%) | 442 (90%) | 51 (10%) | 469 (95%) | 26 (5%) | ||||
| >20 | 72 (69%) | 32 (31%) | 67 (64%) | 37 (36%) | 65 (55%) | 53 (45%) | 82 (69%) | 36 (31%) | ||||
| Missing | 10 | 3 | 13 | 4 | 16 | 7 | 19 | 4 | ||||
| EGFR | <0.001 | <0.001 | ||||||||||
| Negative | 467 (91%) | 45 (9%) | - | - | 493 (87%) | 73 (13%) | - | - | ||||
| Positive | 54 (70%) | 23 (30%) | - | - | 29 (44%) | 37 (56%) | - | - | ||||
| Missing | 1 | 1 | 1 | 1 | ||||||||
| Subtype | <0.001 | <0.001 | <0.001 | <0.001 | ||||||||
| Luminal A-like | 330 (93%) | 23 (7%) | 338 (94%) | 20 (6%) | 314 (94%) | 21 (6%) | 331 (98%) | 6 (2%) | ||||
| Luminal B-like HER2- | 97 (87%) | 15 (13%) | 105 (94%) | 7 (6%) | 127 (84%) | 25 (16%) | 147 (97%) | 5 (3%) | ||||
| Luminal B-like HER2+ | 12 (71%) | 5 (29%) | 16 (94%) | 1 (6%) | 10 (53%) | 9 (47%) | 17 (89%) | 2 (11%) | ||||
| HER2+ | 16 (76%) | 5 (24%) | 13 (62%) | 8 (38%) | 7 (44%) | 9 (56%) | 11 (69%) | 5 (31%) | ||||
| Triple Negative | 45 (71%) | 18 (29%) | 24 (38%) | 39 (62%) | 38 (51%) | 37 (49%) | 32 (43%) | 43 (57%) | ||||
| Missing | 22 | 3 | 24 | 5 | 27 | 10 | 32 | 5 | ||||
| Time-interval BC1-BC2 | 0.04 | 0.8 | 0.2 | 0.1 | ||||||||
| <5 year | 226 (85%) | 39 (15%) | 231(86%) | 37 (14%) | 215 (80%) | 53 (20%) | 235 (87%) | 34 (13%) | ||||
| ≥5 years | 296 (91%) | 30 (9%) | 289 (87%) | 43 (13%) | 308 (84%) | 58 (16%) | 335 (91%) | 32 (9%) | ||||
Abbreviations: BC1 first breast cancer BC2 second breast cancer, EGFR Epidermial growth factor receptor, ER estrogen receptor, HIF Hypoxia-inducible factor, N+ lymph-node metastases, N0 no lymph-node metastases, N number, node status lymph-node status, PR progesterone receptor.
a χ2-test except for date of diagnosis and stage where a χ2-test for trend was used.